267 related articles for article (PubMed ID: 15944869)
21. Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension.
Gürsoy A; Erdoğan MF; Cin MO; Cesur M; Başkal N
Endocr Pract; 2005; 11(5):308-12. PubMed ID: 16191490
[TBL] [Abstract][Full Text] [Related]
22. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
23. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
[TBL] [Abstract][Full Text] [Related]
25. Sibutramine in overweight/obese hypertensive patients.
Sharma AM
Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S20-3. PubMed ID: 11916102
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
[TBL] [Abstract][Full Text] [Related]
27. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
28. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Nakou E; Filippatos TD; Liberopoulos EN; Tselepis AD; Kiortsis DN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 Jul; 9(10):1629-39. PubMed ID: 18570597
[TBL] [Abstract][Full Text] [Related]
29. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
[TBL] [Abstract][Full Text] [Related]
30. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Seimon RV; Espinoza D; Ivers L; Gebski V; Finer N; Legler UF; Sharma AM; James WP; Coutinho W; Caterson ID
Int J Obes (Lond); 2014 Sep; 38(9):1165-71. PubMed ID: 24406481
[TBL] [Abstract][Full Text] [Related]
31. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment.
Heusser K; Engeli S; Tank J; Diedrich A; Wiesner S; Janke J; Luft FC; Jordan J
J Clin Endocrinol Metab; 2007 Apr; 92(4):1560-3. PubMed ID: 17284621
[TBL] [Abstract][Full Text] [Related]
32. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
33. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
[TBL] [Abstract][Full Text] [Related]
34. Long-term weight loss with sibutramine: a randomized controlled trial.
Wirth A; Krause J
JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
[TBL] [Abstract][Full Text] [Related]
35. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
[TBL] [Abstract][Full Text] [Related]
36. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
[TBL] [Abstract][Full Text] [Related]
37. Sibutramine. A review of its contribution to the management of obesity.
McNeely W; Goa KL
Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
[TBL] [Abstract][Full Text] [Related]
38. Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study.
Wirth A; Scholze J; Sharma AM; Matiba B; Boenner G
Diabetes Obes Metab; 2006 Nov; 8(6):674-81. PubMed ID: 17026492
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Gómez-Santos R; Campos-Franco E; Berber A
Adv Ther; 2003; 20(2):101-13. PubMed ID: 12836810
[TBL] [Abstract][Full Text] [Related]
40. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
